Medix Biochemica appoints Dr. Michele Pedrocchi, former Head of Business Development for Roche Diagnostics, to its Board of DirectorsSeptember 1, 2022
- Medix Biochemica announces the appointment Dr. Michele Pedrocchi, former Global Head of Strategy and Business Development for Diagnostics at Roche, to its Board of Directors
- Dr. Pedrocchi brings 25 years of international experience in in-vitro diagnostics, digital health, life sciences and personalized medicine
Medix Biochemica, a global leader in critical in-vitro diagnostics (IVD) raw materials, has announced the appointment of Dr. Michele Pedrocchi to their Board of Directors. Dr. Pedrocchi is a seasoned healthcare executive with more than 25 years of international experience at Roche, spanning in-vitro diagnostics, digital health, life sciences and personalized medicine. He brings expertise in corporate strategy, commercial execution, and business development, following his tenure at Roche, serving as the Global Head of Strategy and Business Development for Diagnostics. Under his leadership, the division pioneered the entry into digital health and executed more than 20 acquisitions and 500 licensing deals.
Building a track record of profitably growing businesses in both emerging and mature markets, Dr. Pedrocchi has previously held multiple international roles at Roche, including General Manager and Regional Head. He has also had an instrumental role in introducing patient selection through companion diagnostics (CDx) and establishing polymerase chain reaction (PCR) as a routine diagnostics methodology.
“I am delighted to be joining the Board of Directors of Medix Biochemica, a company with great potential that provides unique, high-quality components to the diagnostics industry. I am impressed by the recent trajectory of growth and portfolio expansion in a space that has a fundamental impact at various stages of healthcare delivery. I am looking forward to working with the Board and the strong management team on its journey to further elevate Medix Biochemica as the most relevant partner to diagnostics companies,” says Dr. Michele Pedrocchi.
“The Board of Medix Biochemica has governed the transformation of our company from a ‘local’ supplier to a truly international partner to IVD manufacturers. This exciting journey now moves into its next phase. The appointment of Michele strengthens our ability to serve global customers and in parallel, tailor our offerings to individual or local customers. His experience with developing business in new and adjacent market sectors will significantly help us articulate our value proposition to both small and large IVD manufacturers,” says Ann-Christine Sundell, Chairperson, Medix Biochemica Board of Directors.
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies. He received his PhD in Molecular Biology from the University of Zürich and his Master of Science degree in biochemistry and cell biology from the Eidgenössische Technische Hochschule (ETH), Zürich.
For more information visit www.medixbiochemica.com
About Medix Biochemica
With Finnish roots and rapidly growing global branches, Medix Biochemica is a market-leading, independent supplier of critical raw materials to the in vitro diagnostics (IVD) industry worldwide. We develop, produce, and supply high-quality antibodies, antigens, and other critical IVD raw material products to our IVD partners all around the world, enabling the delivery of accurate IVD tests to billions of patients worldwide. Our expertise covers everything from immuno- and molecular diagnostic reagents to biospecimen and custom services. With the most comprehensive raw material portfolio in the IVD world, and a team made up of the best minds in the business, we help shorten our customers’ time to market and build quality into every one of their tests. Medix Biochemica Group employs circa 300 professionals worldwide and we serve our global customers through our local teams in North America, Europe, and China.
Corporate, Finance & Investor,